Navigation Links
Grunenthal Group Acquires Pain Patent Portfolio From Nectid, Inc.
Date:3/22/2011

PRINCETON, N.J., March 22, 2011 /PRNewswire/ -- Nectid, Inc. (www.nectid.com) announced today that it has completed the sale of a number of patents and patents-applications to Grunenthal GmbH (www.grunenthal.com), a European specialty pharmaceutical company that is a pioneer in pain drug discovery and research. The patent portfolio includes a number of novel chemical entities from Nectid's Pain Drug Discovery program and two key drug delivery platforms (www.nectid.com/pipeline_newdrug).

Dr. Veena Rao, President and CEO of Nectid, said, "We are very happy with this patent sale transaction with Grunenthal. This is the second patent deal Nectid has completed in the last 12 months and the patents are among the nineteen of our patents that have been acquired by big pharmaceutical companies in the last two years. We have accumulated a portfolio of 110 NCEs for pain and depression and we expect to file an IND for at least one drug candidate within the next 6-9 months."

About Nectid, Inc.

Based in Princeton, New Jersey, Nectid is a privately held drug discovery company with primary focus on developing novel drug delivery products and novel chemical entities for two therapeutic areas that use one or more common biochemical pathways- Pain and Depression. Nectid applies its deep understanding pain receptor science to develop novel drug candidates that target mu-opioid receptor, norepinephrine reuptake and alpha2delta or NMDA pathways. For more information, visit www.nectid.com.


'/>"/>
SOURCE Nectid, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Introducing the Access Group and Its New Business Entities
2. MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
3. PR Newswire and BIOCOM Purchasing Group Announce Renewal of Exclusive Partnership
4. Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND
5. BioNeutral Group Secures Three Initial Trial Orders for its Ogiene™ Odor Neutralizer & Multi-Purpose Cleaner Product Line
6. Photonic Products Group, Inc. Announces New Sales and Marketing VP
7. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
8. Healthzone Limited Engages The Trout Group for Investor Relations Services
9. BioNeutral Group to Receive Economic Development Incentives
10. 74 Percent EBITDA Improvement at Zeltia Group in 2010
11. Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search firm Slone ... continued commitment to the advancement of the clinical trials segment. Hosted in Miami, ... clinical trial planning and management. , As executive talent specialists in the ...
(Date:1/18/2017)... ... January 18, 2017 , ... Announced ... Manufacturing Innovation Institutes (MII). U.S. Secretary of Commerce Penny Pritzker has announced the ... the Department of Defense has announced the award of a new Advanced Regenerative ...
(Date:1/18/2017)... PA (PRWEB) , ... January 18, 2017 , ... ... operations again at the CHI SCOPE Summit for Clinical Ops Executives (Hyatt Regency ... engaging panel discussions to examine vital clinical research issues such as trial performance ...
(Date:1/18/2017)... , ... January 18, 2017 , ... Thirty-six startup companies ... credits by the Pennsylvania Department of Community and Economic Development in 2016 as part ... located in the University City Keystone Innovation Zone and represent the highest number of ...
Breaking Biology Technology:
(Date:12/16/2016)... Dec 16, 2016 Research and Markets has ... - Global Forecast to 2021" report to their offering. ... The biometric vehicle ... at a CAGR of 14.06% from 2016 to 2021. The market ... projected to reach 854.8 Million by 2021. The growth of the ...
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much ... doors or starting the engine. Continental will demonstrate the ... Las Vegas . Through the combination of ... and Entry) and biometric elements, the international technology company ... vehicle personalization and authentication. "The integration of ...
Breaking Biology News(10 mins):